Gasmi M, Glynn J, Jin M J, Jolly D J, Yee J K, Chen S T
Center for Gene Therapy, Chiron Technologies, San Diego, California 92121, USA.
J Virol. 1999 Mar;73(3):1828-34. doi: 10.1128/JVI.73.3.1828-1834.1999.
A number of human immunodeficiency type 1 (HIV-1)-based vectors have recently been shown to transduce nondividing cells in vivo as well as in vitro. However, if these vectors are to be considered for eventual clinical use, a major consideration is to reduce the probability of unintended generation of replication-competent virus. This can be achieved by eliminating viral genetic elements involved in the generation of replication-competent virus without impairing vector production. We have designed a system to transiently produce HIV-1-based vectors by using expression plasmids encoding Gag, Pol, and Tat of HIV-1 under the control of the cytomegalovirus immediate-early promoter. Our data show that the best vector yield is achieved in the presence of the Rev/Rev-responsive element (RRE) system. However, the constitutive transport element of Mason-Pfizer monkey virus can substitute for RRE and Rev at least to some extent, whereas the posttranscriptional regulatory element of human hepatitis B virus appeared to be inefficient. In addition, we show that high-titer virus preparations can be obtained in the presence of sodium butyrate, which activates the expression of both the packaging construct and the vector genome. Finally, our results suggest that efficient infectivity of vectors defective in the accessory proteins Vif, Vpr, Vpu, and Nef depends on the nature of the target cells.
最近已证明,一些基于1型人类免疫缺陷病毒(HIV-1)的载体在体内和体外均可转导非分裂细胞。然而,如果要考虑将这些载体最终用于临床,一个主要的考虑因素是降低意外产生具有复制能力病毒的可能性。这可以通过消除参与产生具有复制能力病毒的病毒遗传元件来实现,同时又不影响载体的生产。我们设计了一个系统,通过使用在巨细胞病毒立即早期启动子控制下编码HIV-1的Gag、Pol和Tat的表达质粒来瞬时产生基于HIV-1的载体。我们的数据表明,在存在Rev/Rev反应元件(RRE)系统的情况下可实现最佳的载体产量。然而,马森- Pfizer猴病毒的组成型转运元件至少在一定程度上可以替代RRE和Rev,而人类乙型肝炎病毒的转录后调控元件似乎效率不高。此外,我们表明在丁酸钠存在的情况下可以获得高滴度的病毒制剂,丁酸钠可激活包装构建体和载体基因组的表达。最后,我们的结果表明,在辅助蛋白Vif、Vpr、Vpu和Nef中存在缺陷的载体的有效感染性取决于靶细胞的性质。